Conclusions and Relevance In this cohort study, GLP-1 RA use was associated with a lower risk of progression to cirrhosis and mortality among patients with MASLD and diabetes
Remember, consistency matters more than perfection
All licensed GLP-1 medicationssuch as semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda)are administered via subcutaneous injection or, in limited cases, as oral tablets
Among over 500 obese patients with OSAS, long-term tirzepatide treatment led to significant reductions in body weight, AHI, and oxygen desaturation index, with particularly pronounced benefits in patients with concurrent glucose and lipid metabolism abnormalities (52)
These areas integrate metabolic signals and regulate energy balance, making them critical for GLP-1's effects on appetite and glucose homeostasis